Cargando…
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Several therapeutic options are available for metastatic RCC, but responses are almost never complete, and resistance to therapy develops in the vast majority of patients. Consequently, novel treatments are needed to combat resistance to current therapies and to improve patient outcomes. We have app...
Autores principales: | Chen, Chun-Hau, Bhasin, Swati, Khanna, Prateek, Joshi, Mukta, Joslin, Patrick MN., Saxena, Ruchi, Amin, Seema, Liu, Suhu, Sindhu, Shreya, Walker, Sarah R., Catalano, Paul, Frank, David A., Alper, Seth L., Bhasin, Manoj, Bhatt, Rupal S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386754/ https://www.ncbi.nlm.nih.gov/pubmed/30796200 http://dx.doi.org/10.1038/s41389-019-0121-7 |
Ejemplares similares
-
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016) -
Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021) -
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018) -
Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
por: Walther, Thomas, et al.
Publicado: (2021) -
Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023)